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Noninvasive PET Flow Reserve Imaging
to Direct Optimal Therapies for Myocardial
Ischemia
Robert A. deKemp and Rob SB Beanlands
Abstract Nuclear cardiology imaging with SPECT or PET is used widely in North
America for the diagnosis and management of patients with coronary artery disease.
Conventional myocardial perfusion imaging (MPI) can identify areas of reversible
ischemia as suitable targets for coronary artery revascularization by angioplasty or
bypass surgery. However, the accuracy of this technique is limited in patients with
advanced disease in multiple coronary arteries, where there is no normal reference
territory against which to assess the “relative” perfusion defects. We have devel-
oped methods for the routine quantification of absolute myocardial blood flow
(MBF mL/min/g) and coronary flow reserve (stress/rest MBF) using rubidium-82
dynamic PET imaging. The incremental diagnostic and prognostic value of abso-
lute flow quantification over conventional MPI has been demonstrated in several
recent studies. Clinical use of this added information for patient management to
direct optimal therapy and the potential to improve cardiac outcomes remains
unclear, but may be informed by recent progress and widespread clinical adoption
of invasive fractional flow reserve(FFR)-directed revascularization. This paper
presents recent progress in this field, toward noninvasive CFR image-guided
therapy with cardiac PET and SPECT.
Keywords Noninvasive cardiac imaging • Myocardial ischemia • Myocardial
blood flow • Coronary flow reserve • Positron emission tomography
12.1 Introduction
Improvements in diagnostic imaging and therapeutic methods have helped to
reduce the cardiac death rate in Canada and other developed nations over the past
decade [16]. However, cardiovascular disease is still the number one cause of death
in most industrialized countries [3]. Noninvasive diagnostic imaging is used
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increasingly as a “gatekeeper” to help optimize the most effective use of higher-risk
invasive (and costly) diagnostic and interventional procedures, such as coronary
angiography and revascularization.
This work is motivated in part by the recent FAME trials [7, 38] showing that
impaired flow reserve, when used to identify “flow-limiting” epicardial stenoses for
revascularization, improved clinical outcomes (reduced cardiac death and myocar-
dial infarction rates) and lowered the total cost of treatment. The FAME trials used
invasive angiography measurements of fractional flow reserve (FFR), but with
associated risks of embolic stroke and other complications of coronary artery
catheterization that may be avoided with the use of noninvasive imaging methods.
Myocardial perfusion reserve (MPR) imaging using positron emission tomog-
raphy (PET) may enable diagnosis of patients with microvascular disease (uVD) or
nonobstructive diffuse epicardial disease, who should not be recommended for
coronary revascularization, sparing them the unnecessary risks of invasive angiog-
raphy for diagnosis alone. Some enhancements to the conventional methods of PET
flow reserve imaging are proposed for accurate noninvasive imaging of ischemia, to
improve identification of hemodynamically and physiologically significant “flow-
limiting” lesions that are optimal targets for invasive revascularization. According
to recent AHA/NIH publications [28], “Standard tests used to diagnose CAD are
not designed to detect coronary uVD. More research is needed to find the best
diagnostic tests and treatments for the disease.” The flow reserve concepts used in
this study are illustrated in Fig. 12.1, and the specific terms are defined in
Table 12.1.
Current international practice guidelines [1, 2] recommend the use of treadmill
exercise-ECG testing and stress perfusion imaging for the diagnosis of ischemia
(benefit class I, evidence levels A,B) and the use of invasive flow reserve (FFR)
measurements to direct invasive revascularization (benefit class I, IIa, evidence
level A) for the treatment of symptoms in patients with suspected ischemic heart
disease. Despite a wealth of observational data, stress MPI is still not a class 1
(A) indication to direct revascularization in patients with stable ischemic heart
Fig. 12.1 Epicardial (EFR, FFR)microvascular (MPR, CFR) flow reserve measurements using
PET imaging and ICA. Normal values of MPR and CFR are approximately 3–5 (average 4.0) in
young healthy adults without microvascular disease. Normal epicardial vessels have FFR¼ 1.0,
whereas “flow-limiting” stenoses with FFR< 0.75–0.80 can produce myocardial ischemia. See
Table 12.1 for definitions
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disease because there remains insufficient evidence that ischemia-directed therapy
reduces the risk of death and/or myocardial infarction.
In conjunction with, or following exercise-ECG testing, stress myocardial perfu-
sion imaging (MPI) is used widely in North America for the noninvasive diagnosis of
coronary artery disease. While single-photon emission computed tomography
(SPECT) is used most commonly, rubidium-82 (82Rb) PET has been available in
the USA since 1989 for the diagnosis of obstructive coronary artery disease (CAD).
We recently completed enrolment of >15,000 patients in the Canadian multicenter
trial [8] evaluating 82Rb PET as an alternative radiopharmaceutical for myocardial
perfusion imaging (Rb-ARMI). Initial results confirmed the high accuracy (>90%) of
low-dose 82Rb PET-CT for diagnosis of obstructive coronary artery disease in patients
with epicardial stenoses 50–70% [20]. Recent meta-analyses also confirm that PET
has higher accuracy for diagnosis of CAD compared to SPECT, even when using
current cameras with attenuation correction and ECG-gating [24].
Stress perfusion imaging is also used for the assessment of myocardial ischemia,
to identify patients that will benefit from invasive revascularization therapy pro-
cedures such as coronary angioplasty and bypass surgery [15] as shown in Fig. 12.2.
The efficacy of this approach was suggested initially in the nuclear sub-study of the
Table 12.1 Flow reserve terminology
Name Definition
Coronary artery disease (CAD) Focal or diffuse narrowing of an epicardial coronary artery
lumen due to the formation of atherosclerotic plaque (stenosis
or lesion) in the arterial wall
Microvascular disease (uVD) Damage to the inner lining (endothelium) of the
subepicardial small arteries or arterioles that regulate blood
flow to the heart muscle




Ratio of maximal hyperemic stress/rest perfusion (tissue
flow), including the effects of epicardial and microvascular
disease, typically measured using noninvasive PET imaging
(Fig. 12.1)
Microvascular reserve (uVR) Ratio of endothelium-dependent stress/rest MBF in the small
resistance arteries and arterioles
Epicardial flow reserve (EFR) Ratio of epicardial vessel-dependent stress/rest MBF in the
large conduit arteries. The sum total of uVR+EFR is equal to
MPR
Coronary flow reserve (CFR) Ratio of maximal hyperemic stress/rest blood flow in the
epicardial coronary arteries, reflecting the effects of epicar-
dial and microvascular disease. CFR is typically measured
invasively during adenosine stress using the indicator dilution
technique
Fractional flow reserve (FFR) Fraction of pressure maintained across an epicardial stenosis
during hyperemic stress, measured using invasive angiogra-
phy. It is analogous to the relative MPR value, in single-
vessel disease without uVD
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COURAGE trial [37] and confirmed recently in patients from the DUKE registry
[12], showing survival and outcome benefits from invasive revascularization using
angioplasty in addition to optimal medical (drug) therapy, in patients with at least
5 % ischemic myocardium improvement. The ISCHEMIA trial currently in pro-
gress [23] is intended to verify prospectively, in patients with ischemia by physi-
ological testing (for MPI: at least 10 % ischemic left ventricular (LV) myocardium),
whether or not revascularization compared to medical therapy will result in
improved clinical outcomes. This is a pivotal trial intended to prove conclusively
the value of ischemia detection by stress perfusion imaging. However, but it is
important to recognize that conventional stress MPI (using SPECT or PET) will still
underestimate the extent and severity of ischemia from diffuse or multivessel
Fig. 12.2 Patients with moderate-to-severe ischemia in the COURAGE nuclear sub-study (A) had
a lower rate of death or MI when there was a 5 % improvement (reduction) in ischemic burden
following revascularization. In the DUKE nuclear cardiology registry (B), patients with >5 %
ischemia worsening had increased risk of death or MI. Retrospective analysis of ~14,000 SPECT-
MPI patients (C) indicated that the percent ischemic myocardium (>10–15%) predicted lower risk
(log hazard ratio) of death following early revascularization. In patients with less than 10–15 %
ischemic myocardium, medical therapy was the most effective treatment [Reproduced from
(A) [37], (B) [12], and (C) [15].]
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disease (patients with left-main coronary artery disease are excluded) and will
neither identify - nor direct treatment of - high-risk patients with disease of the
coronary microvasculature.
12.2 Myocardial Blood Flow (Perfusion) Imaging
Some limitations of conventional (relative) MPI can be overcome by quantifying
myocardial perfusion blood flow (MBF) in absolute units of mL/min/g. Dynamic
imaging is required starting from the time of tracer injection, to capture the first-
pass transit through the venous-arterial circulation as shown in Fig. 12.3. The
concentration of tracer is measured over time in the arterial blood and myocardial
tissues, and the rate of uptake or transfer from blood to tissue (influx rate K1
mL/min/g) is related to the absolute myocardial perfusion [21]. Flow quantification
restores the true normal-to-diseased tissue contrast (Fig. 12.4), which is otherwise
underestimated by measurement of the tracer retention (net uptake) alone. It also
allows visualization of the stress/rest perfusion or flow reserve (MPR or MFR) as a
measure of the total coronary vascular dilator capacity.
A one-tissue-compartment model is often used to describe the early kinetics
(e.g., 0–5 min) of tracer exchange between the arterial blood supply and myocardial
target tissues. This model has been validated for rubidium-82 (82Rb) imaging in
humans using nitrogen-13 (13N)-ammonia PET as the reference standard [22] and
Fig. 12.3 Quantification of MBF using dynamic PET imaging. Dynamic images are acquired
starting at the time of tracer injection, then activity in the LV cavity and myocardium is measured
over time and fit to a one-tissue-compartment model of the tracer kinetics. The influx rate of tracer
uptake or transfer from blood to tissue (K1 mL/min/g) is related to MBF, according to a tracer
extraction function E(MBF)
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has been demonstrated to give very reproducible results using several investiga-
tional and commercial implementations as shown in Fig. 12.5a, b [9, 27, 31]. Test-
retest repeatability of the method (Fig. 12.5c) is approximately 10–12 % CV
(coefficient of variation) at rest and 6–7 % during pharmacologic stress [11, 30],
comparable to the theoretical expected values verified recently using Monte-Carlo
and analytic simulations [25].
Resting MBF is known to correlate highly with the metabolic demands of
normal cardiac work [4] as shown in Fig. 12.6; therefore, it is common to adjust
the rest of the MBF values to an average reference standard value (e.g., 8500 in
typical patients). There a normal age-related increase in RPP, which also contrib-
utes to a progressive decline in MPR [10]. The adjusted values at rest represent the
expected MBF under conditions of normal controlled systolic blood pressure and
heart rate, which are often elevated in patients undergoing stress MPI. The
RPP-adjusted MPR represents the flow reserve that would be expected in a patient
with normal resting hemodynamics, which may be used to evaluate impairments in
coronary vasodilator function associated with atherosclerosis that are unbiased by
the effects of resting hypertension.
Because of the wide physiological variability in rest MBF values between
patients, interpretation of absolute PET flow studies is recommended to include
both the stress MBF and the stress/rest perfusion reserve in combination [18] as
illustrated in Fig. 12.7. Abnormalities in both flow reserve< 1.5–2 and stress
MBF< 1 mL/min/g have been suggested to represent ischemic tissues that should
be considered for revascularization [17]. The absolute flow increase (stress–rest
MBF delta) has also been proposed as an alternative method to evaluate the
vasodilator response in some studies of vascular endothelial function [36] but has
not been as widely applied in practice.
The diagnostic utility of PET MPR assessment has been confirmed in patients
with multivessel disease [40]. As shown in Fig. 12.8a, there is a 50 % likelihood of
three-vessel disease in patients with a global LV flow reserve that is severely
Fig. 12.4 Polar-maps of MBF (flow), 82Rb uptake (K1 influx rate), and retention (net
influx efflux) demonstrating the effects of nonlinear tracer extraction and washout. MBF esti-
mation restores the true disease-to-normal tissue contrast and increases the sensitivity to detect
focal disease relative to areas of maximal flow
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impaired (MPR¼ 1), whereas the balance of patients presumably have severe
microvascular disease limiting their ability to increase myocardial perfusion from
rest to peak stress. Measurements of absolute MPR also have prognostic value that
is incremental and independent of the standard assessments of relative MPI [41], as
shown in Fig. 12.8b. Patients with normal MPI (SSS< 4) but abnormal flow reserve
(MFR< 2) are at increased risk of cardiac events. In the case of abnormal MPI, if
Fig. 12.5 MBF values measured using the one-tissue-compartment model are highly reproducible
between several investigational (A) and commercial (B) software implementations. Rest and stress
flow values are generally within 15–20 %, allowing multicenter data to be pooled or combined
between vendors. Test–retest repeatability is 7–10 % at stress and rest (C), for single-session back-
to-back scans
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flow reserve is also impaired, then these patients have the highest rate of cardiac
events within the following year. Similar findings have reported in a separate cohort
of ischemic heart disease patients [26]; those with the lowest values of MPR had the
highest cardiac event rates. Despite these observational studies, there is a lack of
evidence proving that revascularization of ischemic myocardium as identified by
absolute flow imaging will result in a lower risk of cardiac death or myocardial
infarction.
Fig. 12.6 MBF at rest is correlated with the heart rate  systolic blood pressure product (RPP).
Peak stress/rest MPR decreases with age as a result of changes in microvascular reactivity and
diffuse atherosclerosis. A median MPR value of 2.0 is observed at age 65 (red star)
Fig. 12.7 Clinical interpretation of PET quantitative MBF measurements at rest, stress, stress/rest
reserve (MPR), and stress–rest delta. The “regional distribution” map is a combination of the flow
reserve and stress flow maps, according to the scheme shown on the bottom right
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12.3 Fractional Flow Reserve Assessment
Invasive coronary angiography methods have been developed over the past two
decades to quantify the functional or hemodynamic significance of epicardial
coronary artery disease, using proximal-distal pressure measurements of the frac-
tional flow reserve ratio (FFR) [13], as illustrated in Fig. 12.9. FFR is defined as the
fractional pressure drop measured across one or more stenoses in an individual
coronary artery. Interestingly, invasive measurements of FFR were originally
validated against 15O-water PET measurements of relative MPR [5]. As shown in
Fig. 12.10, coronary FFR values were similar to the relative MPR on average,
whereas the myocardial FFR shows a small bias of approximately +10 % vs. the
PET analogous values.
Epicardial stenoses with abnormal FFR< 0.75 were initially shown to identify
the presence of myocardial ischemia with high accuracy compared to a positive test
on one or more of three noninvasive methods: exercise thallium planar imaging, or
dobutamine stress echocardiography, or treadmill exercise ECG (Fig. 12.11)
[33, 34]. This FFR threshold is therefore very sensitive for the detection of
ischemia, because it correlates with ischemia on any of the reference standards
above.
Test-retest repeatability of FFR measurements has been reported in the range of
4–7 % CV [6, 29, 32], similar to the precision of PET stress MBF (Fig. 12.12). This
has led to the adoption of a 5 % “gray zone” of uncertainty in FFR measurements
considered to be hemodynamically significant or flow limiting.
The pivotal FAME trial [38] showed that percutaneous coronary intervention
(PCI) revascularization using coronary stenting of anatomically and hemodynam-
ically significant lesions (stenosis 50 % and FFR 0.80) improved cardiac out-
comes (Fig. 12.13) and reduced the total cost of treatment compared to the standard
practice of revascularization for anatomically significant lesions only
Fig. 12.8 Diagnostic utility of MPR (MFR) in multivessel disease is shown on the left [40].
Patients with global flow reserve< 1 have > 50 % probability of three-vessel disease; the
remaining patients have severe microvascular disease. Patients with reductions in flow reserve
(MFR< 2) have lower event-free survival, regardless of whether their relative perfusion (SSS) is
normal or abnormal [41]
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Fig. 12.9 Fractional flow reserve is measured as the ratio of intracoronary pressure distal to a
stenosis and relative to the (proximal normal) aortic pressure during peak adenosine pharmaco-
logic stress. Comparison of the FFR measurements to coronary angiography allows identification
of flow-limiting stenoses that are optimal targets for revascularization
Fig. 12.10 Invasive measurements of FFR were originally validated against 15O-water PET MBF
studies in a group of N¼ 22 patients with single-vessel coronary artery disease. Coronary
(epicardial) FFR produced values that were ~10 % higher than the relative flow reserve (relative
MPR) values. The myocardial (epicardial +microvascular) FFR values corrected for atrial venous
pressure were more accurate on average, but demonstrated an increasing trend versus PET.
Adapted from [5]
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(stenosis> 50–70 %). However, there remains a significant cost (interventional
pressure wires) and patient morbidity (risk of embolic strokes) associated with this
invasive procedure. While FFR provides a useful physiological assessment of epi-
cardial stenoses, it does not assess the severity of microvascular disease and actually
underestimates the functional significance of epicardial lesions in the presence of
microvascular disease [35]. Despite these limitations, FFR has recently been
upgraded to a class I(A) indication in Europe and class IIa(A) in North America for
use in directing revascularization therapy to improve clinical outcomes.
12.4 Noninvasive PET (MPR) vs. Invasive Coronary
Angiography (FFR)
Reductions in the supply of blood to the myocardium are caused by two separate
consequences of disease: (1) epicardial coronary stenoses and (2) microvascular
dysfunction. The “flow-limiting” epicardial stenoses should be identified ideally
Fig. 12.11 Fractional flow reserve (FFR) compared to ischemia testing in N¼ 45 patients, using
exercise ECG, thallium imaging, and stress echo [34]. Abnormal FFR< 0.75 was reported to have
88 % sensitivity and 100 % specificity to identify ischemia according to stress echo or exercise
thallium imaging or exercise-ECG tests combined(*), but specificity decreases dramatically in the
“gray zone” between the FFR cutoff values of 0.75 to 0.80 and when FFR is compared individually
to the ischemia standard tests. At the FFR cutoff value< 0.80 commonly used to direct revascu-
larization, fewer than 50 % of subjects had exercise-ECG, stress echo, and thallium tests that were
all positive for ischemia
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as targets for revascularization, whereas patients with diffuse or microvascular
disease may be better treated with targeted aggressive medical therapies such
as lipid-lowering statins or other novel drug treatments under development
to improve endothelial function by increasing nitric-oxide bioavailability, for
example.
Myocardial and fractional flow reserve measurements represent different
hemodynamic effects of microvascular and epicardial disease. The interrelated
physiological interpretation of PET MFR vs. invasive FFR measurements has
been the subject of several recent reviews [14, 19]. The discordance between FFR
and MPR is attributed to the differences in epicardial vs microvascular disease
(Fig. 12.14c) and is consistent with our PET data in over 3,000 patients
(Fig. 12.14a, b).
As illustrated in Fig. 12.1, noninvasive PET imaging of MPR measures the
capacity to increase perfusion (and tracer delivery) in the downstream microvas-
culature within the myocardium, reflecting the combined “total” effects of micro-
vascular and epicardial disease. Invasive FFR measures the pressure drop across a
Fig. 12.12 Test-retest repeatability of back-to-back FFR measurements 10 min apart (4 % CV),
reanalyzed from the DEFER study by [32]. The measurement (or classification) uncertainty is shown
as the red-green colorbar, reflecting the probability that a revascularization decision would change
with repeat measurement. The conventional diagnostic uncertainty or “gray zone” of 0.75–0.80 is
shown as the grey-green colorbar
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single epicardial stenosis during hyperemic stress, representing the peak flow
compared to the (restored or expected) normal flow in the absence of stenosis.
FFR determines whether a particular epicardial lesion is “flow limiting”; however,
this measurement assumes that maximal peak-stress vasodilatation was achieved in
the downstream microvasculature. Therefore, in the presence of microvascular
dysfunction, FFR can be overestimated (i.e., the severity of disease underestimated)
due to a submaximal stress flow response, resulting in underdiagnosis and potential
undertreatment of the disease [35].
There is a wide variation in reported MFR values at a given lesion stenosis
severity (Fig. 12.15a) confirming the influence of confounding variables such
as peak-MFR and/or microvascular flow reserve (uVR). Measurements of total
MFR alone cannot separate the fundamental difference in stress flow responses
present in the epicardial conduit arteries vs. the microvascular resistance vessels.
This effect is illustrated in Fig. 12.15b showing that a 70 % stenosis can appear to
have normal or abnormal FFR depending on the peak hyperemic flow response
(peak-MFR).
We have proposed a simple model describing MPR as the sum total of uVR
and epicardial CFR as shown in Fig. 12.15c. This model is consistent with
Fig. 12.13 The FAME randomized controlled trial in N¼ 1005 patients showed that clinical
outcome was improved (87 % vs. 82 % event-free survival; p¼ 0.02) using FFR-guided revascu-
larization by PCI with drug-eluting stents in patients with intermediate-grade stenosis> 50 % and
FFR< 0.80. The FFR-guided approach also resulted in 30 % fewer stents placed per patient
(p< 0.001) and 11 % lower overall costs including the added FFR pressure wires [38]
12 Noninvasive PET Flow Reserve Imaging to Direct Optimal Therapies for. . . 165
previous observations that MFR decreases with increasing lesion stenosis%, but
at different reference levels depending on the burden of microvascular disease.
uVR is presumed to be independent of epicardial stenosis severity, also consistent
with previous invasive measurements of microcirculatory resistance (IMR)
[39]. The model predicts that a particular threshold value (EFR¼MPR – uVR)
for epicardial coronary revascularization will only improve symptoms of ischemia
in patients without severe microvascular disease, e.g., with uVR> 0, as shown in
Fig. 12.15d. Conversely, myocardial ischemia may be overestimated in young
patients without uVD, where an “apparent ischemic” stress perfusion defect in a
patient with very high peak-MFR may still be above the true ischemic threshold
of stress MBF.
Fig. 12.14 Discordance between FFR and MPR is due to the physiological differences in focal
epicardial vs. diffuse or microvascular disease. (A) Invasive [and (B) noninvasive] measures of
CFR [and absolute MPR] vs. FFR [and relative MPR] measurements can be discordant in some
patients, due to the different physiological consequences of focal vs. diffuse microvascular
disease (C). Adapted from [19]
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12.5 Conclusion
Noninvasive nuclear imaging of myocardial blood flow (MBF) and coronary flow
reserve (CFR) is now feasible as part of the clinical routine using positron emission
tomography (PET) imaging. PET measurements of absolute MBF are reliable and
reproducible between imaging centers and software methods, with test–retest
repeatability below 10 % coefficient of variation. Ischemic thresholds have been
proposed for stress MBF and coronary flow reserve in the range of 1.5 [mL/min/g]
and 1.0 [stress/rest MBF], respectively. Prospective trials are needed to determine
whether patient outcomes can be improved using these ischemic thresholds to direct
appropriate revascularization vs. optimal medical therapies.
Fig. 12.15 Total myocardial perfusion (flow) reserve (MPR) is a function of epicardial stenosis
severity (0–100%) andmicrovascular vasodilator response (uVR) as shown in (A,B). In patients with
severemicrovascular (endothelial) dysfunction (e.g. uVR¼−0.5), invasivemeasurement of fractional
flow reserve (FFR)may appear normal in coronary lesions up to 90% stenosis (C), due to the absence
of hyperemic flow response (peak-MFR¼1.0). Epicardial flow reserve (EFR¼MPR–uVR) may be
useful to identify flow-limiting lesions associated with myocardial ischemia (D)
12 Noninvasive PET Flow Reserve Imaging to Direct Optimal Therapies for. . . 167
Open Access This chapter is distributed under the terms of the Creative Commons Attribution-
Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any
noncommercial use, distribution, and reproduction in any medium, provided the original author(s)
and source are credited.
The images or other third party material in this chapter are included in the work’s Creative
Commons license, unless indicated otherwise in the credit line; if such material is not included in
the work’s Creative Commons license and the respective action is not permitted by statutory
regulation, users will need to obtain permission from the license holder to duplicate, adapt or
reproduce the material.
References
1. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. J Am Coll Cardiol.
2011;58(24):e44–e122.
2. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of
Patients with Stable Ischemic Heart Disease. J Am Coll Cardiol. 2012;60(24):e44–e164.
3. Canadian Institutes of Health Research Annual Report 2010–11. Moving Forward CIHR
Performance across the Spectrum: From Research Investments to Knowledge Translation.
4. Czernin J, Porenta G, Brunken R, Krivokapich J, Chen K, Bennett R, Hage A, Fung C,
Tillisch J, Phelps ME. Regional blood flow, oxidative metabolism, and glucose utilization in
patients with recent myocardial infarction. Circulation. 1993;88(3):884–95.
5. De Bruyne B, Baudhuin T, Melin JA, et al. Coronary flow reserve calculated from pressure
measurements in humans. validation with positron emission tomography. Circulation.
1994;89:1013–22.
6. de Bruyne B, Bartunek J, Sys SU, Pijls NH, Heyndrickx GR, Wijns W. Simultaneous coronary
pressure and flow velocity measurements in humans. Feasibility, reproducibility, and hemo-
dynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope
index, and fractional flow reserve. Circulation. 1996;94(8):1842–9.
7. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, M€obius-
Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstr€om T, Oldroyd KG,
Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Ju¨ni P. Fearon
WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy
in stable coronary disease. N Engl J Med. 2012;367(11):991–1001.
8. deKemp RA, Wells GA, Beanlands RSB. Rubidium-82 – An Alternative Radiopharmaceutical
for Myocardial Imaging (Rb-ARMI) 2009–2015. http://clinicaltrials.gov/ct2/show/
NCT01128023
9. deKemp RA, DeClerck J, Klein R, Pan X-B, Nakazato R, Tonge C, Arumugam P, Berman DS,
Germano G, Beanlands RS, Slomka PJ. Multi-software reproducibility study of stress and rest
myocardial blood flow assessed with 3D dynamic PET-CT and a one-tissue-compartment
Model of 82Rb Kinetics. J Nucl Med. 2013;54:571–577.
10. deKemp RA, Klein R, Renaud J, Garrard L, Wells GA, Beanlands R. Patient age, gender and
hemodynamics are independent predictors of myocardial flow reserve as measured with
dipyridamole stress PET perfusion imaging. J Nucl Med. 2014;55(S1):79.
11. Efseaff M, Klein R, Ziadi MC, Beanlands RS, deKemp RA. Short-term repeatability of resting
myocardial blood flow measurements using rubidium-82 PET imaging. J Nucl Cardiol.
2012;19(5):997–1006.
12. Farzaneh-Far A, Phillips HR, Shaw LK, Starr AZ, Fiuzat M, O’Connor CM, Sastry A, Shaw
LJ, Borges-Neto S. Ischemia change in stable coronary artery disease is an independent
predictor of death and myocardial infarction. JACC Cardiovasc Imaging. 2012;5(7):715–24.
168 R.A. deKemp and R.S. Beanlands
13. Gould KL, Kirkeeide RL, Buchi M. Coronary flow reserve as a physiologic measure of
stenosis severity. J Am Coll Cardiol. 1990;15(2):459–74.
14. Gould KL. Does coronary flow trump coronary anatomy? JACC Cardiovasc Imaging.
2009;2:1009–23.
15. Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, Hayes SW,
Cohen I, Germano G, Berman DS. Impact of ischemia and scar on the therapeutic benefit
derived from myocardial revascularization vs. medical therapy among patients undergoing
stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32(8):1012–24.
16. Heart and Stroke Foundation Annual report on Canadians Health. A Perfect Storm of Heart
Disease Looming on Our Horizon, January 25, 2010.
17. Johnson NP, Gould KL. Physiological basis for angina and ST-segment change: PET-verified
thresholds of quantitative stress myocardial perfusion and coronary flow reserve. JACC
Cardiovasc Imaging. 2011;4:990–8.
18. Johnson NP, Gould KL. Integrating noninvasive absolute flow, coronary flow reserve, and
ischemic thresholds into a comprehensive map of physiological severity. JACC Cardiovasc
Imaging. 2012;5:430–40.
19. Johnson NP, Kirkeeide RL, Gould KL. Is discordance of coronary flow reserve and fractional
flow reserve due to methodology or clinically relevant coronary pathophysiology? JACC
Cardiovasc Imaging. 2012;5:194–202.
20. Kaster T, Mylonas I, Renaud JM, Wells GA, Beanlands RSB, deKemp RA. Accuracy of
low-dose rubidium-82 myocardial perfusion imaging for detection of coronary artery disease
using 3D PET and normal database interpretation. J Nucl Cardiol. 2012.
21. Klein R, Renaud JM, Ziadi MC, Beanlands RSB, deKemp RA. Intra- and inter-operator
repeatability of myocardial blood flow and myocardial flow reserve measurements using
rubidium-82 pet and a highly automated analysis program. J Nucl Cardiol. 2010;17:600–16.
22. Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, deKemp RA. Quantification of
myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging.
2007;34:1765–74.
23. Maron D, Boden W, Ferguson B, Harrington R, Stone G, Williams D. International study of
comparative health effectiveness with medical and invasive approaches (ISCHEMIA). https://
clinicaltrials.gov/ct2/show/NCT01471522
24. Mc Ardle BA, Dowsley TF, deKemp RA, Wells GA, Beanlands RS. Does rubidium-82 PET
have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary
disease? A systematic review and meta-analysis. J Am Coll Cardiol. 2012;60(18):1828–37.
25. Moody J, Murthy V, Lee B, Corbett J, Ficaro E. Variance Estimation for Myocardial Blood
Flow by Dynamic PET. IEEE Trans Med Imaging. 2015 May 13. [Epub ahead of print]
26. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, Blankstein R, Dorbala S,
Sitek A, Pencina MJ, Di Carli MF. Improved cardiac risk assessment with noninvasive
measures of coronary flow reserve. Circulation. 2011;124(20):2215–24.
27. Nesterov SV, Deshayes E, Sciagra R, Settimo L, Declerck JM, Pan XB, Yoshinaga K,
Katoh C, Slomka PJ, Germano G, Han C, Aalto V, Alessio AM, Ficaro EP, Lee BC, Nekolla
SG, Gwet KL, deKemp RA, Klein R, Dickson J, Case JA, Bateman T, Prior JO, Knuuti
JM. Quantification of myocardial blood flow in absolute terms using (82)Rb PET imaging: the
RUBY-10 Study. JACC Cardiovasc Imaging. 2014;7(11):1119–27.
28. NIH-NHLBI website. What is Coronary Microvascular Disease? http://www.nhlbi.nih.gov/
health/health-topics/topics/cmd. Accessed September 2015.
29. Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, Barbato E, Hamilos M,
Mangiacapra F, Heyndrickx GR, Wijns W, Pijls NH, De Bruyne B. Fractional flow reserve for
the assessment of nonculprit coronary artery stenoses in patients with acute myocardial
infarction. JACC Cardiovasc Interv. 2010;3(12):1274–81.
30. Ocneanu A, Adler A, Renaud J, Beanlands R, deKemp R, Klein R. Reproducible tracer
injection profile improves the test-retest repeatability of myocardial blood flow quantification
with 82Rb PET. J Nucl Med. 2015;56(S3):207.
12 Noninvasive PET Flow Reserve Imaging to Direct Optimal Therapies for. . . 169
31. Pan X-B, DeClerck J. Validation syngo PET Myocardial Blood Flow. Siemens Healthcare:
White Paper 2012.
32. Petraco R, Sen S, Nijjer S, Echavarria-Pinto M, Escaned J, Francis DP, Davies JE. Fractional
flow reserve-guided revascularization: practical implications of a diagnostic gray zone and
measurement variability on clinical decisions. JACC Cardiovasc Interv. 2013;6(3):222–5. doi:
10.1016/j.jcin.2012.10.014. Erratum in: JACC Cardiovasc Interv. 2013;6(4):431.
33. Pijls NH, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL. Experimental basis of
determining maximum coronary, myocardial, and collateral blood flow by pressure measure-
ments for assessing functional stenosis severity before and after percutaneous transluminal
coronary angioplasty. Circulation. 1993;87:1354–67.
34. Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J, Koolen JJ,
Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of
coronary-artery stenoses. NEJM. 1996;334(26):1703–8.
35. Pijls NH, Tonino PA. The CRUX of maximum hyperemia: the last remaining barrier for
routine use of fractional flow reserve. JACC Cardiovasc Interv. 2011;4(10):1093–5.
36. Schindler TH, Zhang X-L, Prior JO, Cadenas J, Dahlbom M, Sayre J, Schelbert
HR. Assessment of intra- and inter-observer reproducibility of rest and cold-pressor-test
stimulated myocardial blood flow with 13N-ammonia and PET. Eur J Nucl Med Mol Imaging.
2007;34:1178–88.
37. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous
coronary intervention to reduce ischemic burden: Results from the clinical outcomes utilizing
revascularization and aggressive drug evaluation (COURAGE) trial nuclear sub-study. Circu-
lation. 2008;117:1283–91.
38. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for
guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213–24.
39. Yong ASC, Ho M, Shah MG, Ng MKC, Fearon WF. Coronary microcirculatory resistance is
independent of epicardial stenosis. Circ Cardiovasc Interv. 2012;5:103–8.
40. Ziadi MC, deKemp RA, Williams K, Beanlands RSB. Does quantification of myocardial flow
reserve using rubidium-82 positron emission tomography facilitate detection of multi-vessel
coronary artery disease? J Nucl Cardiol. 2012;19:670–80.
41. Ziadi MC, deKemp RA, Williams K, Beanlands RSB. Impaired myocardial flow reserve on
rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients
assessed for myocardial ischemia. J Am Coll Cardiol. 2011;58:740–8.
170 R.A. deKemp and R.S. Beanlands
